Advisor Group Holdings, Inc. Janux Therapeutics, Inc. Transaction History
Advisor Group Holdings, Inc.
- $39.8 Billion
- Q4 2024
A detailed history of Advisor Group Holdings, Inc. transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Advisor Group Holdings, Inc. holds 3,235 shares of JANX stock, worth $118,983. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,235
Previous 1,168
176.97%
Holding current value
$118,983
Previous $53,000
226.42%
% of portfolio
0.0%
Previous 0.0%
Shares
4 transactions
Others Institutions Holding JANX
# of Institutions
181Shares Held
40.3MCall Options Held
115KPut Options Held
681K-
Ra Capital Management, L.P. Boston, MA9.17MShares$337 Million5.81% of portfolio
-
Janus Henderson Group PLC London, X02.52MShares$92.8 Million0.06% of portfolio
-
Paradigm Biocapital Advisors LP New York, NY2.4MShares$88.3 Million3.93% of portfolio
-
Black Rock Inc. New York, NY2.34MShares$86.2 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.14MShares$78.6 Million0.0% of portfolio
About Janux Therapeutics, Inc.
- Ticker JANX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 41,663,000
- Market Cap $1.53B
- Description
- Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...